Show simple item record

dc.contributor.authorGullhaug, Anna
dc.contributor.authorHaakensen, Vilde Drageset
dc.contributor.authorDe Ruysscher, Dirk
dc.contributor.authorSimone, Charles B.
dc.contributor.authorHotca-Cho, Alexandra E.
dc.contributor.authorChhabra, Arpit M.
dc.contributor.authorHellebust, Taran Annette Paulsen
dc.contributor.authorPaulsen, Erna-Elise
dc.contributor.authorDimopoulos, Maria P.
dc.contributor.authorJohansen, Safora
dc.date.accessioned2024-10-09T12:29:14Z
dc.date.available2024-10-09T12:29:14Z
dc.date.issued2024-02-29
dc.description.abstractBackground: Patients treated for lung cancer (LC) often experience locoregional failure after initial treatment. Due to technological advances, thoracic reirradiation (re-RT) has become a viable treatment option. We sought to investigate the use of thoracic re-RT in LC patients over a time period characterized by technological advances in a large, multi-center cohort.<p> <p>Methods and materials: LC patients treated with thoracic re-RT in two University Hospitals from 2010-2020 were identified. Clinical variables and RT data were extracted from the medical records and treatment planning systems. Overall survival (OS) was calculated from the last day of re-RT until death or last follow up. <p>Results: 296 patients (small cell LC n=30, non-small cell LC n=266) were included. Three-dimensional conformal radiation therapy was the RT technique used most frequently (63%), and 86% of all patients were referred for re-RT with palliative treatment intent. During the second half of the study period, the use of thoracic re-RT increased in general, more patients received curativere-RT, and there was an increased use of stereotactic body radiation therapy (SBRT). Median time between initial RT and re-RT was 18 months (range 1-213 months). Only 83/296 patients had combined treatment plans that allowed for registration of combined doses to organs at risk (OAR). Most of the combined doses to OAR were below recommendations from guidelines. Multivariate analysis showed superior OS (p<0.05) in patients treated with curative intent, SBRT or intensity modulated radiation therapy or had excellent performance status prior to re-RT. <p>Conclusions: The use of re-RT increased in the second half of the study period, although 2020 did not follow the trend. The use of SBRT and IMRT became more frequent over the years, yet the majority received palliative re-RT. Combined dose plans were only created for one third of the patients.en_US
dc.identifier.citationGullhaug, Haakensen, De Ruysscher, Simone, Hotca-Cho, Chhabra, Hellebust, Paulsen, Dimopoulos, Johansen. Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes. Journal of Medical Imaging and Radiation Sciences. 2024en_US
dc.identifier.cristinIDFRIDAID 2260617
dc.identifier.doi10.1016/j.jmir.2024.02.004
dc.identifier.issn1939-8654
dc.identifier.issn1876-7982
dc.identifier.urihttps://hdl.handle.net/10037/35148
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalJournal of Medical Imaging and Radiation Sciences
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 Elsevieren_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleLung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomesen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)